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ABSTRACT
Establishing the in vivo diagnosis of Alzheimer’s
disease (AD) or other dementias relies on clinical
criteria; however, the accuracy of these criteria
can be limited. The diagnostic accuracy is 77%
for a clinical diagnosis of AD, even among
experts. We performed a review through PubMed
of articles related to specific diagnostic modali-
ties, including APOE genotyping, cerebrospinal
fluid (CSF) testing, fludeoxyglucose F 18 positron
emission tomography (PET), amyloid PET, tau
PET, computed tomography (CT), single-photon
emission CT, magnetic resonance imaging (MRI),
and B12 and thyroid-stimulating hormone
screening, to determine the specificity and sen-
sitivity of each test used in the clinical diagnosis
of AD. We added a novel immunomagnetic
reduction assay that provides ultrasensitivity for
analyzing the levels of plasma tau and beta
amyloid 42 (Ab42). The sensitivity and specificity
of the current diagnostic approach (structural CT
or MRI with screening labs) remain low for clin-
ical detection of AD and are primarily used to
exclude other conditions. Because of limited
diagnostic capabilities, physicians do not feel
comfortable or skilled in rendering a clinical
diagnosis of AD. Compounding this problem is
the fact that inexpensive, minimally invasive
diagnostic tests do not yet exist. Biomarkers
(obtained through CSF testing or PET imaging),
which are not routinely incorporated in clinical
practice, correlate well with pathologic changes.
While PET is particularly costly and difficult to
assess, CSF measures of tau and beta amyloid are
not costly, and these tests may be worthwhile
when the tiered approach proposed here war-
rants further testing. There is a need for devel-
oping bloodborne biomarkers that can aid in the
clinical diagnosis of AD. Here we present a
streamlined questionnaire-enriched,
biomarker-enriched approach that is more
cost-effective than the current diagnosis of
exclusion and is designed to increase clinical
confidence for a diagnosis of dementia due to AD.
Keywords: Biomarkers; Clinical assessment;
Dementia; Diagnostic algorithm
INTRODUCTION
The original criteria described by the working
group formed by the National Institute of
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
CAD8F06039796B6E.
M. N. Sabbagh (&)  D. Fayard  J. Shi
Department of Neurology, Barrow Neurological
Institute, Phoenix, AZ, USA
e-mail: Neuropub@barrowneuro.org
Lih-Fen Lue
Center for Neurodegenerative Research, Arizona
State University, Tempe, AZ, USA
Neurol Ther (2017) 6 (Suppl 1):S83–S95
DOI 10.1007/s40120-017-0069-5
Neurological and Communicative Disorders
and Stroke (NINCDS) and the Alzheimer’s
Disease and Related Disorders Association
(ADRDA) (referred to as the NINCDS-ADRDA
criteria) [1] set forth tiers of probability for
confidence in a diagnosis of Alzheimer’s dis-
ease (AD). The highest tier was ‘‘definite AD’’,
which was autopsy confirmed. The next tier
was ‘‘probable AD’’, which presented as a pro-
gressive amnestic disorder with dementia that
affected two areas of cognition and functional
impairment without other causes identified.
‘‘Possible AD’’ was described as a progressive
amnestic syndrome that could have other
contributors to the cognitive impairment (e.g.,
stroke, epilepsy).
These definitions stayed constant for
almost 3 decades. In 2011, the National Insti-
tute on Aging–Alzheimer’s Association
(NIA-AA) working group met to review and
update the diagnostic criteria (Table 1). The
first principle is that, to have AD, one must
have dementia [2]. The updated definition of
dementia is cognitive impairment that inter-
feres with the ability to function at work or at
usual activities that is associated with a decline
from a previous level of functioning and that
is not caused by delirium or a psychiatric dis-
order [2]. Features discovered on history and
examination should include the involvement
of at least two cognitive domains, such as
memory, reasoning and judgment, visuospa-
tial, language, personality, behavior, and
comportment. According to the 2011 NIA-AA
guidelines, the diagnosis of AD requires that
certain core criteria be met [2, 3]: report of
cognitive concern by patient, caregiver, or
clinician; gradual onset over months to years;
evidence of longitudinal cognitive decline;
differential diagnosis that rules out vascular,
traumatic, and medical causes of cognitive
decline; and objective evidence of impairment
in two or more cognitive domains and inabil-
ity to function at work or usual activities. Like
the older NINCDS-ADRDA criteria, the tiers of
probability included ‘‘proven AD’’, ‘‘probable
AD’’, and ‘‘possible AD’’. In this schema, pro-
ven AD is that which is confirmed by widely
accepted neuropathology criteria at autopsy or
after biopsy. Probable AD refers to evidence of
amnestic predominant dementia that has an
insidious onset, history of progressive wors-
ening, and no evidence of cardiovascular
Table 1 Diagnostic guidelines for Alzheimer’s disease
from the National Institute on Aging–Alzheimer’s Asso-




Cognitive or behavioral symptoms that
interfere with the ability to function
at work or at usual activities,
represent a decline from previous
levels of functioning, and are not
explained by delirium or major
psychiatric disorder
The cognitive or behavioral
impairment involves a minimum of
two of the following domains:
impaired ability to acquire and
remember new information, impaired
reasoning and handling of complex
tasks, impaired visuospatial abilities,
impaired language functions, and





Meets criteria for dementia, in addition
to insidious gradual onset, history of
worsening cognition by report or
observation, or initial and most
prominent cognitive deficits in either
amnestic (impaired learning or recent







Atypical course (sudden onset,
insufficient historical detail, or
objective progressive decline) or
etiologically mixed presentation
(meets all core clinical criteria, but has
evidence of cerebrovascular disease,
features of dementia with Lewy
bodies, or evidence of another
neurologic or non-neurologic disease




Patient meets the clinical and cognitive
criteria for AD dementia, and the
neuropathologic examination
demonstrates the presence of the AD
pathology
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disease, dementia with Lewy bodies, fron-
totemporal dementia, or aphasia. Possible AD
refers to amnestic predominant dementia that
has an atypical course or an etiologically
mixed presentation, such as possible comor-
bidities that could contribute to the dementia
presentation.
The NIA-AA working group reviewed bio-
marker evidence to support a clinical diagno-
sis of AD. They defined AD pathophysiology
as either (1) beta amyloid (Ab) seen on cere-
brospinal fluid (CSF) testing or amyloid posi-
tron emission tomography (PET) or (2)
neuronal injury as documented by demon-
stration of tau on CSF testing, fludeoxyglucose
F 18 (18F-FDG) PET, or evidence of atrophy on
structural magnetic resonance imaging (MRI).
They concluded that probable AD with evi-
dence of AD pathophysiology strengthened
the probability of AD as the pathology but left
this criterion as informative but not essential.
In contrast, the International Working Group
(IWG) [4] described the specific clinical phe-
notype (typical AD) as episodic memory
impairment that occurred gradually and pro-
gressively and was reported by the patient or
informant as having persisted for more than
6 months; in addition, the patient must dis-
play objective evidence of an amnestic syn-
drome of the hippocampal type based on
significantly impaired performance on an
episodic memory test. In contrast to the
report of the NIA-AA working group, the IWG
did consider biomarker evidence as not only
supportive but as also essential. They defined
in vivo evidence of Alzheimer’s pathology as
one of the following: decreased Ab1–42, toge-
ther with increased total tau (T-tau) or phos-
pho-tau (P-tau) in the CSF; increased tracer
retention on amyloid PET; or AD autosomal
dominant mutation present in PSEN1, PSEN2,
or APP.
The consequence of guidelines that fail to
incorporate biomarker evidence of support is
that biomarker evidence is not routinely used in
clinical practice. Historically, the diagnosis of
AD has been approached by excluding other
health conditions. In other words, the diagnosis





The timely diagnosis of AD is an unmet need in
clinical practice. Physicians are reluctant to make
a diagnosis of dementia and, more specifically, a
diagnosis of dementia caused by AD. The con-
sequence of this reluctance is that diagnosis is
delayed by an average of 2–3 years after symp-
tom onset [5, 6]. In addition, one study evalu-
ating the clinical diagnosis found that up to 50%
of patients with any form of dementia are not
formally diagnosed during life [7].
Not only is there a delay in diagnosis, but
there is also evidence that a diagnosis of AD can
often be quite inaccurate. Twenty-five percent
of patients clinically diagnosed with probable
AD during their lifetime did not have evidence
of AD at autopsy [8]. In a clinical imag-
ing/pathology series of 57 individuals clinically
diagnosed with AD, 13 (23%) had no (n = 7) or
sparse (n = 6) Ab plaques at autopsy. Twelve of
these individuals were diagnosed neuropatho-
logically with a dementia disease other than
AD, most frequently caused by aggregation of
tau. Thus, diagnostic accuracy is 77% for a
clinical diagnosis of AD, even among the
experts. In another study, florbetaben PET was
consistent with histopathologic results in all
12 patients for whom standard uptake value
ratios (SUVRs) were available [9].
These data show that it is imperative that the
clinical diagnosis be improved without a com-
mensurate increase in cost. Thus, the diagnosis
of AD dementia must transition from a diag-
nosis of exclusion to a diagnosis of inclusion. A
solution might include a tiered approach with
the incorporation of questionnaires and
biomarkers. A representative outline of current
practice is shown in Fig. 1.
A NEW TIERED APPROACH
TO DIAGNOSING ALZHEIMER’S
DISEASE
A new tiered approach to diagnosing AD could
allow a more accurate diagnosis with lower cost
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and higher sensitivity. Herein, a revised
approach to the current diagnostic algorithm is
proposed. The rationale for each step is
explained. This article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects per-
formed by any of the authors.
Step 1: Structured Questionnaires
Informant-based questionnaires could be
incorporated into the diagnostic process. These
questionnaires could be used routinely in both
clinical and research settings to differentiate
between individuals with amnestic mild cogni-
tive impairment (MCI) and AD from individuals
who are cognitively normal [10, 11]. The
Informant Questionnaire on Cognitive Decline
in the Elderly (IQCODE) and the Ascertain
Dementia 8-Item Informant Questionnaire
(AD8) have demonstrated good diagnostic
accuracy for AD and have been found to corre-
late well with other conventional cognitive
screening tests, such as the Mini-Mental State
Examination (MMSE) [12, 13].
The Alzheimer’s Questionnaire (AQ) is a
21-item, informant-based assessment designed
for ease of use in the clinical setting that has
demonstrated high sensitivity and specificity
for both amnestic MCI and AD [14, 15]. The
concurrent validity of the AQ with other
established measures of cognition was
demonstrated by Malek-Ahmadi et al. [16], who
found that the AQ correlates strongly with the
Clinical Dementia Rating Sum of Boxes and
correlates moderately with the MMSE and
Montreal Cognitive Assessment (MoCA).
The AD8 is also a screening interview. It is a
brief, sensitive screening measure that reliably
differentiates between individuals with and
without dementia. The AD8 comprises eight
yes/no questions asked of an informant to rate
change by querying memory, orientation,
judgment, and function [12], and it takes
approximately 2–3 min for the informant to
complete. The AD8 has a sensitivity of 84% and
specificity of 80% as well as excellent ability to
discriminate between non-demented older
adults and those with mild dementia (92%)
regardless of the cause of impairment. The
sensitivity and specificity of AD8 were deter-
mined in a 2006 study involving 255
patient-informant dyads, and these data were
subsequently compared with the independently
derived Clinical Dementia Rating and with
patients’ performance on neuropsychologic
tests [12]. Like the AQ, the AD8 is highly cor-
related with the Clinical Dementia Rating and
neuropsychologic testing.
The IQCODE was developed as a way of
measuring cognitive decline from a premorbid
level using informant reports. Each item is rated
on a 5-point scale from 1, meaning ‘‘much
better’’, to 5, meaning ‘‘much worse’’, and the
ratings are averaged over the 16 items to give a
score ranging from 1 to 5, with 3 representing
no change on any item. In clinical situations, a
screening cutoff of 3.44? on the Short IQCODE
is a reasonable compromise for balancing sen-
sitivity and specificity.
The informant-based questionnaires as a
group have high sensitivity, specificity, and area
under the curve (AUC) in differentiating normal
controls from AD patients. The sensitivity and
specificity of the AD8 are 85% and 86%,
respectively, with an AUC of 0.83 [12]. The
sensitivity and specificity of the IQCODE are
79% and 82%, respectively, with an AUC of 0.85
[13]. The sensitivity and specificity of the AQ
are 99% and 96%, respectively, with an AUC of
0.99. All of these questionnaires are simple to
administer, informant-based, and not
bFig. 1 A proposed stepwise approach to assessing a patient
for dementia. It incorporates details that include the
traditional diagnosis of exclusion while preparing the
reader for the possibility of incorporating advanced
biomarkers. CBC complete blood count, CSF cere-
brospinal fluid, CT computed tomography, FDG-PET
fludeoxyglucose F 18 positron emission tomography,
GPCOG General Practitioner Assessment of Cognition,
LFTs liver function tests, Mini-Cog Mini-Cognitive
Assessment Instrument, MMSE Mini-Mental State Exam-
ination, MoCA Montreal Cognitive Assessment, MRI
magnetic resonance imaging, PET positron emission
tomography, SLUMS Saint Louis University Mental
Status, TDP-43 TAR DNA-binding protein 43, TSH
thyroid-stimulating hormone. Copyright Eli Lilly and Co.,
all rights reserved. Used with permission
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time-consuming. More importantly, they allow
structure for the primary care physician or spe-
cialist to capture incident cognitive decline.
For the purposes of specificity, additional
questions to detect dementia with Lewy bodies
(e.g., the Lewy Body Composite Risk Score
[LBCRS]) [17] and frontotemporal dementia [18]
could be added without significant increases in
the burden of time.
Step 2: Aggregate Risk Analysis
Epidemiologic studies have shown that a variety
of health conditions increase the risk for AD
dementia. The patient’s medical history is
gathered at the time of the consultation to
ascertain whether medical conditions such as
diabetes, hypertension, hypercholesterolemia,
head injury, or cardiovascular disease are pre-
sent. During the past decade, models have been
proposed to quantify individual risk for devel-
oping AD on the basis of a patient’s individual
demographics. These models incorporate age,
family history, health conditions, and other
factors to estimate risk (Table 2). On the basis of
aggregate risk scoring, a score of less than 5 is
low risk, 5-12 is moderate risk, and 12 and
above is high risk [19, 20]. Doing an aggregate
risk analysis during the consultation enriches
the probability of AD if the score is high.
Step 3: Bedside Cognitive Screening
A variety of brief cognitive tests were developed
for assessing general cognitive function. The use
of the AD8 in conjunction with a brief assess-
ment, such as assessing the patient’s ability to
remember a word list, could improve clinicians’
ability to detect dementia in the primary care
setting to 97% for dementia and 91% for MCI
[12]. Below are a few of the more commonly
used and easier to administer measures. Several
diagnostic tests are now available for use in
primary care as alternatives to the MMSE.
Mini-Mental State Examination (MMSE)
The MMSE is a copyrighted test that has fre-
quently been used for the initial assessment of
cognitive impairment. The MMSE has
increasing sensitivity as the decline of the score
over time is taken into account [21]. It is quick
and easy to administer and can track the overall
progression of cognitive decline, but it is not
considered to be a good test for the definitive
diagnosis of AD [22].
Mini-Cognitive Assessment Instrument
(Mini-Cog)
The Mini-Cog combines an uncued three-item
recall test with a clock-drawing test that serves
as a recall distractor [23]. The Mini-Cog and the
MMSE have similar sensitivity (76% vs. 79%,
respectively) and specificity (89% vs. 88%,
respectively) for dementia. The shortness of the
Mini-Cog is a distinct advantage when the goal
is to improve recognition of cognitive impair-
ment in primary care [23].
Table 2 Aggregate risk scoring for risk factors for Alz-
heimer’s disease Adapted from Kivipelto et al. [19] and
Norton et al. [20]
Risk factor Odds ratio
A first-degree relative with AD 3.0






Systolic BP[140 mmHg 2.2
BMI[30 kg/m2 2.3
Cholesterol[6.5 mmol/l 1.9
APOE e4 positivity 4.0
History of stroke 2.4
History of myocardial infarction 2.5
Untreated type 2 diabetes mellitus 2.0
Low physical activity (sedentary) 1.7
Continuation of smoking 2.3
BMI body mass index, BP blood pressure, LOC loss of
consciousness
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Short Blessed Test (SBT)
The SBT is easily administered by a nonphysi-
cian and has been shown to discriminate
among mild, moderate, and severe cognitive
deficits [24, 25]. It consists of the items in the
Blessed Orientation-Memory-Concentration
Test, includes three orientation questions
(month, year, and time of day), counting from
20 to 1, saying the months backward, and
recalling a five-item name and address memory
phrase [24]. The SBT is quite sensitive to early
cognitive changes due to AD.
Saint Louis University Mental Status (SLUMS)
The SLUMS is a 30-point, 11-item, clini-
cian-administered screening questionnaire that
tests for attention, numeric calculation, imme-
diate and delayed recall, animal naming, digit
span, clock drawing, figure recognition/size
differentiation, and immediate recall of facts
from a paragraph [26]. In particular, the clock
drawing test is designed to assess impairment in
executive function. Due to copyright issues, the
Veterans Administration has stopping using the
MMSE, and they and others now use the SLUMS
instead.
Montreal Cognitive Assessment (MoCA)
The MoCA is a brief cognitive screening tool
with a high sensitivity and specificity for
detecting MCI in patients who perform within
the normal range of the MMSE [27]. The limi-
tation of the MoCA may be its more complex
interpretation, and it requires training to be
administered properly.
Step 4: Physical and Neurologic
Examination
The potential for reversible dementias is com-
monly pursued in the diagnostic consideration
but the yield is quite low. In one meta-analysis,
conditions requiring neuroimaging made up
only 2.2% of cases with reversible cause seen in
less than 10% of total cases. In fact, the
meta-analysis found that only 0.6% of dementia
cases actually reversed partially or fully [28].
A comprehensive physical and neurologic
examination can detect incident focality (e.g.,
hemiparesis, asymmetry of tone or reflexes,
hemi-sensory changes) and gait abnormalities.
This examination can be used to detect cere-
brovascular disease, mass lesions, parkinsonism,
or communicating hydrocephalus [29]. Patients
who show no salient neurologic abnormalities
on examination have a lower probability that
imaging studies will find an abnormality that
needs intervention.
Though controversial and counter to con-
ventional practice, we recommend that in the
absence of abnormal neurologic findings on
examination, structural imaging should not be
obtained. The current practice guideline is to
incorporate structural imaging as part of the
diagnostic evaluation for AD [2, 3] to exclude
other conditions. This practice comes from the
previous American Academy of Neurology
guidelines. In a class II study, 5% of patients had
a clinically significant structural lesion (i.e., a
potentially treatable lesion) but no features in
their history or examination that would have
predicted the lesion. Thus, the recommenda-
tion is to include CT or MRI in the patient’s
initial evaluation to avoid missing any treat-
able conditions [30]. However, this percentage
means the number needed to treat (NNT) is 1 in
20. At an estimated cost of $1000 per scan, that
is $20,000 per identified treatable condition.
The obvious question is, ‘‘Does obtaining
structural imaging add value?’’ In one study,
data from MRI did not significantly improve
discrimination performance in predicting all
causes of dementia beyond that of a model that
incorporated demographic, cognitive, health,
lifestyle, physical function, and genetic data. In
other words, clinical information might be just
as good as structural imaging [31]. Another
study found that CT impacted the diagnosis
only 12% of the time and treatment 11% of the
time [32]. Other recommendations include that
structural imaging is useful only with the fol-
lowing caveats, as recommended by Wollman
and Prohovnik: ‘‘we suggest that neuroimaging
should be considered: (1) when clinical exper-
tise is insufficient; (2) as a complement to
specific likelihood ratios; and (3) in specific
types of patients, for whom clinical evaluation
is inappropriate or inadequate’’ [33]. Efforts are
underway to develop algorithms to enhance the
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utility of structural imaging in clinical practice
and to increase the sensitivity for detection and
differentiation of dementia [34, 35]. Until such
time as these technologies mature, our recom-
mendation is to obtain structural imaging only
when abnormal neurologic findings are found
on examination for the purposes of an initial
dementia evaluation. This position statement
does not exclude the utility of structural imag-
ing in the tiered approach. If there is any evi-
dence of abnormality on neurologic
examination that is referable to the central
nervous system, then structural imaging is
warranted.
Step 5: Laboratory Screening Tests
Combined with Advanced Bloodborne
Biomarkers
Like structural imaging, screening for deficien-
cies in B12 and thyroid stimulating hormone are
low-cost, high-yield tests for identifying
reversible causes of dementia [2, 36]. However,
they are insufficient for detecting AD, because
they are only used to exclude other conditions.
To move from a diagnosis of exclusion to a
diagnosis of inclusion, one must consider
including apolipoprotein E (APOE) genotyping.
Also controversial, the rationale for doing so is
as follows. The lifetime risk for developing AD
for a patient who is homozygotic for the APOE
e4 is 91%, and the lifetime risk for a patient who
is heterozygotic for APOE e4 is 47% [37]. APOE
e4 carrier status is highly predictive of AD; an
APOE e4 carrier who is symptomatic has a
94–97% chance of having AD [38]. In one study,
the clinical diagnosis of AD improved from 55%
to 84% when APOE e4 carrier status was added
to the model [39]. In addition, 50% of MCI
subjects who are APOE e4 carriers progress to AD
dementia in 3 years compared to 20% of non--
APOE e4 carriers [40]. MCI subjects (amnestic
subtype) who are APOE e4 carriers convert to AD
[99% of the time [40]. APOE e4 carriers are 26
times more likely to progress in cognitive
decline. In addition, the presence of the APOE
e4 allele predicts AD pathology on PET imaging
[41].
APOE genotyping could be added to dis-
ease-associated biomarkers to improve diagnos-
tic yield. Disease-associated biochemical
markers are present in the blood; however, the
measurable amounts are only 10% of those
present in the CSF. As a result, the sensitivity
and accuracy of the technology used for mea-
suring the levels of these disease-associated
proteins in the blood are critical, in addition to
other issues that also affect CSF biomarker
measurements [42–45]. Recent advances in
technology have improved the sensitivity and
accuracy of the measurement of these disease
biochemicals in the blood. Among these tech-
nologies, the immunomagnetic reduction (IMR)
technology stands out in its ability to measure
three important AD pathology-associated pro-
teins (Ab40, Ab42, and tau) [46]. Due to the
unique principles on which this technology is
based, IMR assays show ultrasensitivity in the
detection of low amounts of the proteins in the
non-blood-cell fraction of blood samples,
plasma, collected from subjects diagnosed with
preclinical AD and clinical AD dementia
bFig. 2 New conceptual framework for assessment of
dementia due to Alzheimer’s disease (AD). The primary
diagnostic steps (tier 1) are indicated by the circled
numbers. The supplemental diagnostic steps (tier 2) are
indicated by the circled letters. The net cost per patient
associated with tier 1 is less than $1200 USD. The
sensitivity of tier 1 diagnosis is[90%; the specificity is yet
to be determined. Because CT and MRI have a very low
probability of supplying meaningful information, we
advocate forgoing these studies in most patients. However,
if normal pressure hydrocephalus (NPH), parkinsonism,
focal symptoms, or a history of cerebrovascular accidents
(CVAs) are present, these imaging studies are warranted.
AD8 Ascertain Dementia 8-Item Informant Question-
naire, AQ Alzheimer’s Questionnaire, CSF cerebrospinal
fluid, CT computed tomography, FDG fludeoxyglucose F
18, FTD frontotemporal dementia, IMR immunomagnetic
reduction, IQCODE Informant Questionnaire on Cogni-
tive Decline in the Elderly, IWG International Working
Group, LBCRS Lewy Body Composite Risk Score, MCI
mild cognitive impairment, Mini-Cog Mini-Cognitive
Assessment Instrument, MMSE Mini-Mental State Exam-
ination, MoCA Montreal Cognitive Assessment, MRI
magnetic resonance imaging, PET positron emission
tomography, TSH thyroid-stimulating hormone. Used
with permission from Barrow Neurological Institute
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[47–50]. In a pilot study, the main objective was
to assess the Ab40, Ab42, and tau levels measured
by the ultrasensitive IMR assays in plasma
samples. When two cohorts were combined
with a cutoff value of 382.68 (pg/ml)2, the
product of Ab2 and tau achieved 92% accuracy
with a sensitivity of 96% and a specificity of
90% [46]. Although these new technologies
have not yet been directly correlated with neu-
ropathologic findings, there have been studies
that attempt to correlate CSF levels and
pathology. A 2008 study by Chiu et al. evalu-
ated the combination of an abnormally low Ab2
level in the CSF and an abnormally high tau
level in the CSF and found that this combina-
tion predicted the presence of AD pathologic
features with a sensitivity of 91.6%, a specificity
of 85.7%, and an overall accuracy of 90.2% [48].
Step 6: Apply IWG Criteria in the Clinical
Diagnosis of AD
As mentioned in the introduction, IWG [4]
incorporates biomarker data into the clinical
diagnosis. Biomarker evidence of AD increases
the probability that a patient has AD. By the
IWG-2 criteria, Kaplan-Meier survival probabil-
ity estimates of progressing to AD dementia
exceed 90% in 5 years, suggesting positive bio-
marker evidence enriches the probability of
progression [4]. However, the question of which
specific biomarker is most predictive remains
unanswered.
DISCUSSION
In this article, we propose a new algorithm for
detecting dementia associated with AD. The
rationale behind this algorithm is that the
historical medical evaluation of dementia due
to AD is inaccurate 25% of the time, that the
diagnosis of AD has been, but should no
longer be, a diagnosis of exclusion, that
physicians do not feel confident in making a
diagnosis of AD dementia, and that there is
often a delay in diagnosis of 2–3 years [5, 6].
Technology is becoming available that greatly
improves the diagnostic accuracy of AD. We
present a novel algorithm that incorporates a
structured history, an aggregate risk assess-
ment, a cognitive screening measure, a
through neurologic examination, and incor-
poration of biomarkers such as APOE and IMR
assay. The use of this algorithm could improve
the accuracy of a diagnosis of dementia due to
AD to [90% without escalation of costs. This
novel algorithm is summarized in Fig. 2. The
algorithm must be assessed for efficacy but has
the potential for accurately diagnosing a sig-
nificant percentage of patients with AD,
which could increase physician confidence.
The resulting reduction in the time to diag-
nose patients might reduce the total morbid-
ity. This outcome will certainly be the case
with the advent and introduction of the dis-
ease-modifying therapies that are currently
being developed.
A tiered approach allows additional tests to
be added as needed. If there is focality on the
examination (parkinsonism, gait abnormality,
spasticity, or hemiparesis), then structural
imaging could be added. If the subject is a
non-APOE e4 carrier, then amyloid PET or CSF
testing for AD biomarkers could be attained. If
the aggregate risk is low, then a more
biomarker-intense approach could be taken. In
short, this tiered system allows for flexibility.
Since most AD dementia patients are likely to be
APOE e4 positive or are likely to have high
screening scores for risk and impairment, in
most cases, additional testing might not be
necessary. Future research should include vali-
dation of the updated algorithm and determi-
nation of outcomes.
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